Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Bank of America

Bank of America began coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research note published on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $22.00 price objective on the stock.

Several other equities analysts have also commented on AARD. Cantor Fitzgerald started coverage on Aardvark Therapeutics in a research report on Monday. They set an “overweight” rating and a $50.00 price target on the stock. Royal Bank of Canada started coverage on Aardvark Therapeutics in a research report on Monday. They set an “outperform” rating and a $21.00 price target on the stock.

Aardvark Therapeutics Stock Performance

NASDAQ AARD opened at $10.14 on Monday. Aardvark Therapeutics has a 1-year low of $9.21 and a 1-year high of $19.58.

Insiders Place Their Bets

In other Aardvark Therapeutics news, CFO Nelson Sun acquired 10,000 shares of the company’s stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $160,000.00. Following the acquisition, the chief financial officer now directly owns 99,484 shares of the company’s stock, valued at $1,591,744. This trade represents a 11.18 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Tien-Li Lee acquired 16,542 shares of the company’s stock in a transaction on Friday, February 14th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $264,672.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,496,175 shares in the company, valued at $23,938,800. The trade was a 1.12 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.